Floatz logo

Ifx-Hu2.0

Skin Squamous Cell Carcinoma

TuHURA Biosciences, Inc.vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Skin Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Prednisone
Dana-Farber Cancer Institute
Phase 4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Regeneron Pharmaceuticals
Phase 3BB
Sirolimus
Dana-Farber Cancer Institute
Phase 4BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB

View all 50 →

Same molecule, other indications

Ifx-Hu2.0 is also rated in:

cutaneous neuroendocrine carcinomaActive
B
Indicative · Phase 2/3
60 / 100
View asset →
skin carcinomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative · Early Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →